Susan A. Davidson

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Inherited Mutations in Women With Ovarian Carcinoma

Barbara M. Norquist, Maria I. Harrell, Mark F. Brady et al. · JAMA Oncology · 2015 · 764 citations · Full text

Medicine, Genetics, Oncology +17

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Robert L. Coleman, Mark F. Brady, Thomas J. Herzog et al. · The Lancet Oncology · 2017 · 602 citations · Full text

Medicine, Gynecology, Oncology +15

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

John K. Chan, Mark F. Brady, Richard T. Penson et al. · New England Journal of Medicine · 2016 · 367 citations · Full text

Medicine, Oncology, Pharmacology +14